Group 1 - JPMorgan Chase & Co. increased its stake in Kanglong Chemical (03759.HK) by purchasing 1,498,061 shares at an average price of HKD 21.9333 per share, totaling approximately HKD 32.8574 million [1] - Following the acquisition, JPMorgan's total holdings in Kanglong Chemical rose to 25,541,112 shares, increasing its ownership percentage from 6.67% to 7.09% [1]

增持后，JPMorgan Chase & Co.最新持好仓数目为25,541,112股，持好仓比例由6.67%上升至7.09%。 | 股份代號: | 03759 | | --- | --- | | 上市法國名稱: | 康龍化成(北京)新藥技術股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 28/12/2025 - 28/01/2026 | 格隆汇1月28日丨根据联交所最新权益披露资料显示，2026年1月23日，康龙化成(03759.HK)获JPMorgan Chase & Co.以每股均价21.9333港元增持好仓149.81 万股，涉资约3285.74万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 費出或涉及的股每股的平均價 | | | | 相有概念的股份数据 | 佔已發行的 有關事件的日 | | --- | --- | --- | --- | --- | --- | --- | | | 份數目 | | | | | (詩參閱上述*註解)有投票權股 (日/月/年) | | | | | | | | 份自分 市 | | CS20260128E00213 | J ...

Core Viewpoint - The market experienced increased volatility in Q4 2025, with A-shares and Hong Kong stocks showing mixed performance, while sectors like AI computing and semiconductors thrived, contrasting with weaker performances in real estate and pharmaceuticals [1] Group 1: Market Performance - The Shanghai Composite Index rose by 2.22% in Q4 2025, while the Hang Seng Index fell by 4.56% [1] - The technology growth sector, particularly AI computing and semiconductors, showed significant gains, while industries such as real estate and pharmaceuticals faced challenges [1] Group 2: Fund Manager Performance - Star fund managers like Fu Pengbo and Li Xiaoxing achieved over 60% returns in 2025, focusing on AI computing and semiconductors [2] - Balanced allocation funds, such as Zhu Shaoxing's, demonstrated stability with a 20% annual return, benefiting from diversified investments across various sectors [3][14] Group 3: Investment Strategies - Fu Pengbo's fund increased its allocation to data center cooling and computing-related companies, with a top ten stock concentration of 70.38% [5] - Li Xiaoxing emphasized AI hardware innovation and semiconductor investments, with a focus on domestic advancements in the semiconductor industry [6] Group 4: Traditional Value Investments - Fund managers like Zhang Kun and Liu Yanhun maintained positions in traditional sectors like consumer goods and pharmaceuticals, despite facing net value pressures [8][12] - Liu Yanhun's fund experienced a 5.85% decline in Q4, reflecting the challenges faced by traditional value sectors [12] Group 5: Policy and Market Outlook - Fund managers noted the impact of "anti-involution" policies on corporate fundamentals, suggesting a shift towards supply-side optimization [17] - Despite market rebounds, equity assets are still viewed as attractive, with a focus on high-quality listed companies as scarce income-generating assets [18]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | 證券代號 (如上市) | | 說明 | | A 股 (深圳證券交易所)) (股份代號: 300759) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | ...

智通财经APP讯，康龙化成(03759)发布公告，于2026年1月28日，该公司根据于2021年7月12日临时股东 大会、A股类别股东大会及H股类别股东大会审议通过批准的特别决议案2021年A股限制性股票激励计 划已于2026年1月28日向本集团员工发行8.16万股A股。 另外，公司根据于2022年5月31日临时股东大会、A股类别股东大会及H股类别股东大会审议通过批准的 特别决议案2022年A股限制性股票激励计划已于2026年1月28日向本集团员工发行56.57万股A股。 ...

另外，公司根据于2022年5月31日临时股东大会、A股类别股东大会及H股类别股东大会审议通过批准的 特别决议案2022年A股限制性股票激励计划已于2026年1月28日向本集团员工发行56.57万股A股。 康龙化成（300759）(03759)发布公告，于2026年1月28日，该公司根据于2021年7月12日临时股东大 会、A股类别股东大会及H股类别股东大会审议通过批准的特别决议案2021年A股限制性股票激励计划 已于2026年1月28日向本集团员工发行8.16万股A股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 | | 否 | | | 證券代號 (如上市) | | 說明 | | A 股 (深圳證券交易所)) (股份代號: 300759) | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | ...

Group 1 - The global biotech and pharmaceutical investment and financing activities are expected to rebound significantly in 2025, driven by the robust development of innovative drug technology platforms, leading to a comprehensive recovery in the CXO industry and sustained industry prosperity into 2026 [1] - The Chinese CRO market is projected to return to a growth trajectory in 2025, with a notable 19% year-on-year increase in IND numbers and a substantial rise in BD transaction amounts, indicating a vibrant domestic innovative drug market [1] - The demand side globally is showing a strong rebound, establishing a solid foundation for growth, with biotech financing reaching a historical high in Q4 2025 and multinational pharmaceutical companies experiencing a recovery in demand [1] Group 2 - WuXi AppTec (药明康德) is expected to report impressive performance in 2025, with adjusted net profit increasing by 41.3%, driven by the TIDES business, which has seen revenue growth exceeding 90% [2] - WuXi Biologics has reached a record high of 945 projects, with a 30% growth in dual monoclonal and ADC projects, indicating a strong pipeline for future commercialization [2] - WuXi AppTec's subsidiary, WuXi STA, is focusing on the ADC/XDC sector, with revenue growth exceeding 40% in 2025 and an increase in global market share to over 24% [2] Group 3 - The Chinese clinical CRO market is at a clear turning point, with Tigermed (泰格医药) benefiting from the industry recovery, as order prices stabilize and the domestic clinical pipeline grows alongside improved financing conditions [3] Group 4 - Global CDMO giants are accelerating expansion, with optimistic performance guidance; Fujifilm is expected to secure $8 billion in new orders in 2025, reflecting strong demand for large molecule CDMO services [4] - Charles River anticipates an improvement in order trends starting in H2 2025, with a forecast for revenue growth in its safety assessment business by H2 2026, serving as an early indicator of recovery in the CXO industry [4] Group 5 - Investment recommendations include focusing on leading clinical CRO platforms like Tigermed and niche leaders such as Pruis, as well as front-end CRO companies with shorter order fulfillment cycles and greater marginal elasticity [5] - In the CDMO sector, attention is advised on leading companies in the peptide supply chain, ADC beneficiaries, and those with forward-looking layouts in small nucleic acids, as well as companies with significant potential for marginal traction from large products [5]

数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 截至2026年1月28日 13:15，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 1.70%，兴齐眼药上涨1.39%，艾力斯上涨0.67%；英科医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 东海证券指出，商务部等九部门联合印发的关于促进药品零售行业高质量发展的意见，从转型、支付、 供应、整合四大维度构建行业发展框架，推动行业从"单一卖药"向"健康服务"转型。政策明确鼓励兼并 重组与横向并购，叠加医保定点待遇与基层医疗机构平权、医保个人账户家庭共济等举措，将加速单体 药店出清，行业集中度有望加速提升；优化外配处方审核，打通线下药店处方堵点，允许企业自建药学 服务平台，加速处方外流和市场扩容；鼓励零售药店扩大经营范围，开展健康咨询、中医药文化、养老 照护、便民零售等，打造综合健康服务体。建议关注资金实力雄厚、并购整合能力强，合规运营与精细 ...

创新药概念局部活跃，消息面上，新修订的《中华人民共和国药品管理法实施条例》将于5月15日起施 行。国家药监局表示，这是条例实施二十多年来，首次全面修订。支持以临床价值为导向研究和创制新 药，提升仿制药质量和疗效。 中信证券研报称，2026年1月，阿里健康、京东健康两家头部医药电商平台相继正式发布面向医生的AI 医疗应用产品。看好头部医药电商平台凭借上游药企、下游C端用户资源，以及其母公司具备的AI基模 能力与产品能力，在ToD AI医疗应用领域脱颖而出，并率先跑通商业模式，实现AI医疗对主业的增收 赋能。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年1月28日 11:09，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，兴齐眼药领涨 1.42%，新和成上涨1.27%，片仔癀上涨0.27%；英科医疗领跌2.47%，华兰生物下跌2.22%，恩华药业下 跌2.22%。医疗创新ETF ...